Peter Koetsier has joined the board of Medicinal Cannabis Industry Australia (MCIA) in a move that will see him work closely with his predecessor at Cann Group, Peter Crock.
Koetsier took over from Crock, the MCIA chair, as Cann Group CEO in January. The pair, along with the rest of the board, will now work together “for the mutual interest of members and stakeholders”.
“MCIA is pleased to welcome Peter to the board, bringing with him a strong pharmaceutical and business perspective,” Crock said. “It is important to ensure that, as the peak industry body, the board of MCIA has the relevant skills to support the continued growth of the industry.”
Prior to joining Cann Group, Koetsier was head of Asia Pacific for French biopharmaceutical company Ipsen.
Previous roles include general manager of Australia/New Zealand with Ipsen and senior management positions with Astra/Zeneca UK, and Bristol-Myers Squibb in Europe.
MCIA said it will continue to build an industry “based on legitimacy, credibility, and recognition for the Australian sector in domestic and international arenas”.
